Revelation Biosciences (REVB) Other financing activities (2020 - 2025)
Revelation Biosciences (REVB) posted quarterly Other financing activities of -$3.0 million for Q4 2025, down 155.85% year-over-year from $5.4 million in Q4 2024, and down 189.29% quarter-over-quarter from $3.4 million in Q3 2025.
Revelation Biosciences (REVB) Other financing activities (2020 - 2025) Analysis & Trends
Revelation Biosciences (REVB) has reported Other financing activities for 5 consecutive years, with -$3.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities fell 155.85% year-over-year to -$3.0 million; the TTM figure through Dec 2025 stood at $5.8 million (up 6.69% YoY), while the FY2025 annual figure was $363000.0, down 93.3% from the prior year.
- Other financing activities declined to -$3.0 million in Q4 2025 per REVB's latest filing, from $3.4 million in the prior quarter.
- Across five years, Other financing activities topped out at $14.0 million in Q4 2023 and bottomed at -$5.4 million in Q2 2024.
- Historically, Other financing activities has averaged $2.2 million across 4 years, with a median of $5074.0 in 2022.
- Annual changes were most pronounced in 2024 — Other financing activities tumbled 61.39% — and 2025, when it slumped 155.85%.
- Revelation Biosciences' Other financing activities stood at $5061.0 in 2022, then surged by 277117.43% to $14.0 million in 2023, then sank by 61.39% to $5.4 million in 2024, then plunged by 155.85% to -$3.0 million in 2025.
- Business Quant data shows REVB's Other financing activities at -$3.0 million in Q4 2025, $3.4 million in Q3 2025, and $5.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - |
| 10 | Revelation Biosciences | 4.13 Mn | -7.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.03 Mn |
| Dec 31, 2025 | -3.03 Mn |
| Sep 30, 2025 | 3.39 Mn |
| Sep 30, 2025 | 3.39 Mn |
| Dec 31, 2024 | 5.42 Mn |
| Dec 31, 2024 | 5.42 Mn |
| Jun 30, 2024 | -5.42 Mn |
| Jun 30, 2024 | -5.42 Mn |
| Mar 31, 2024 | 5.42 Mn |
| Mar 31, 2024 | 5.42 Mn |
| Dec 31, 2023 | 14.03 Mn |
| Dec 31, 2023 | 14.03 Mn |
| Sep 30, 2022 | 5,061.00 |
| Sep 30, 2022 | 5,061.00 |
| Jun 30, 2022 | -5,061.00 |
| Jun 30, 2022 | -5,061.00 |
| Mar 31, 2022 | 5,074.00 |
| Mar 31, 2022 | 5,074.00 |
| Dec 31, 2020 | 68.18 Mn |
| Dec 31, 2020 | 68.18 Mn |